Abstract
In two healthy male subjects the disposition of deuterated N-(2H3) acetyl-5-aminosalicylic acid (d3-ac-5-AS) was investigated after a single rectal dose of 500 mg d3-ac-5-AS. Urine and plasma were analysed by h.p.l.c. and gas chromatography mass-spectrometry. Peak concentrations of around 0.5 microgram/ml occurred within 6 h and plasma concentrations declined thereafter with a half-life (t1/2) of about 6 h which was confirmed by urinary excretion data. Renal clearance of d3-ac-5-AS ranged between 200 and 300 ml/min and only 4.4-11.2% of the dose could be recovered in the 48 h urine. Since no undeuterated ac-5-AS could be detected in any of the plasma and urine samples an irreversible acetylation of 5-AS is assumed in man.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
- Campieri M., Lanfranchi G. A., Bazzocchi G., Brignola C., Sarti F., Franzin G., Battocchia A., Labo G., Dal Monte P. R. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981 Aug 8;2(8241):270–271. doi: 10.1016/s0140-6736(81)90523-7. [DOI] [PubMed] [Google Scholar]
- Das K. M., Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet. 1976 Nov-Dec;1(6):406–425. doi: 10.2165/00003088-197601060-00002. [DOI] [PubMed] [Google Scholar]
- Fischer C., Maier K., Klotz U. Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. J Chromatogr. 1981 Oct 9;225(2):498–503. doi: 10.1016/s0378-4347(00)80303-5. [DOI] [PubMed] [Google Scholar]
- Fischer C., Maier K., Stumpf E., von Gaisberg U., Klotz U. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur J Clin Pharmacol. 1983;25(4):511–515. doi: 10.1007/BF00542120. [DOI] [PubMed] [Google Scholar]
- Houston J. B., Cassidy M. K. Rate limiting steps in metabolite kinetics: formation of 5-acetylaminosalicylate after administration of 5-aminosalicylate. J Pharm Pharmacol. 1982 Aug;34(8):536–538. doi: 10.1111/j.2042-7158.1982.tb04786.x. [DOI] [PubMed] [Google Scholar]
- Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
- Pieniaszek H. J., Jr, Bates T. R. Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats. J Pharm Sci. 1979 Oct;68(10):1323–1325. doi: 10.1002/jps.2600681036. [DOI] [PubMed] [Google Scholar]
- Stec G. P., Ruo T. I., Thenot J. P., Atkinson A. J., Jr, Morita Y., Lertora J. J. Kinetics of N-acetylprocainamide deacetylation. Clin Pharmacol Ther. 1980 Nov;28(5):659–666. doi: 10.1038/clpt.1980.218. [DOI] [PubMed] [Google Scholar]
- Vree T. B., Tijhuis M. W., Baakman M., Hekster C. A. Analysis of N4-trideuteroacetylsulphamerazine and its metabolites sulphamerazine and N4-acetylsulphamerazine in man by means of high-performance liquid chromatography and mass spectrometry. Biomed Mass Spectrom. 1983 Mar;10(3):114–119. doi: 10.1002/bms.1200100303. [DOI] [PubMed] [Google Scholar]
- Willoughby C. P., Piris J., Truelove S. C. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol. 1980;15(6):715–719. doi: 10.3109/00365528009181520. [DOI] [PubMed] [Google Scholar]
- van Hees P. A., Bakker J. H., van Tongeren J. H. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980 Jul;21(7):632–635. doi: 10.1136/gut.21.7.632. [DOI] [PMC free article] [PubMed] [Google Scholar]